Company intelligence / Profile preview

Merus

Utrecht, Utrecht, Netherlandsmerus.nl ↗

Ownership: Public · MRUS
Employees: ~321
Development stage: Phase 3

Overview

Summary of current clinical results highlights encouraging single-agent activity of petosemtamab in head & neck cancers as well as combination therapy potential[1][3][4].

Therapeutic areas: Oncology
Modalities: Full-length human bispecific antibodies (Biclonics®)Trispecific antibodies (Triclonics®)Antibody-drug conjugates (ADClonics®) derived from Biclonics®
Industry: Biotech

Drug pipeline

6 assets

zenocutuzumab

Approved

5 more assets in the full pipeline.

Request access →

Partnerships

Betta Pharmaceuticals Co. Ltd. for development/commercialization rights in China to MCLA‑129[4]Eli Lilly and Company[5]Ono Pharmaceutical Co., Ltd.[5]

Financials

Market cap: $6.8B
Total revenue: $12.2M
Enterprise value: $6.3B

Beyond the preview

Go deeper on Merus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merus.

Explore the full profile